EUVIMEDEUVIMED entdecken
Crossref

A Prognostic Methylation-Driven Two-Gene Signature in Medulloblastoma

Gustavo Lovatto Michaelsen, Lívia Dos Reis Edinger da Silva, Douglas Silva de Lima, Mariane da Cunha Jaeger, André Tesainer Brunetto, Rodrigo Juliani Siqueira Dalmolin, Marialva Sinigaglia

Journal of Molecular Neuroscience · 2024

DOI: 10.1007/s12031-024-02203-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Molecular Neuroscience, 2024. Verfasst von Gustavo Lovatto Michaelsen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Children's Cancer Institute, Porto Alegre, 90620-110, RS, Brazil. Hauptthemen laut MEDLINE: Medulloblastoma, DNA Methylation, Cerebellar Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 100 Literaturangaben. Gefördert von: National Council for Scientific and Technological Development (CNPq, MCTI, Brazil), Conselho Nacional de Desenvolvimento Científico e Tecnológico, Childrens' Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Medulloblastoma (MB) is one of the most common pediatric brain tumors and it is estimated that one-third of patients will not achieve long-term survival. Conventional prognostic parameters have limited and unreliable correlations with MB outcome, presenting a major challenge for patients' clinical improvement. Acknowledging this issue, our aim was to build a gene signature and evaluate its potential as a new prognostic model for patients with the disease. In this study, we used six datasets totaling 1679 samples including RNA gene expression and DNA methylation data from primary MB as well as control samples from healthy cerebellum. We identified methylation-driven genes (MDGs) in MB, genes whose expression is correlated with their methylation. We employed LASSO regression, incorporating the MDGs as a parameter to develop the prognostic model. Through this approach, we derived a two-gene signature (GS-2) of candidate prognostic biomarkers for MB (CEMIP and NCBP3). Using a risk score model, we confirmed the GS-2 impact on overall survival (OS) with Kaplan-Meier analysis. We evaluated its robustness and accuracy with receiver operating characteristic curves predicting OS at 1, 3, and 5 years in multiple independent datasets. The GS-2 showed highly significant results as an independent prognostic biomarker compared to traditional MB markers. The methylation-regulated GS-2 risk score model can effectively classify patients with MB into high and low-risk, reinforcing the importance of this epigenetic modification in the disease. Such genes stand out as promising prognostic biomarkers with potential application for MB treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MedulloblastomaDNA MethylationCerebellar NeoplasmsBiomarkers, TumorTranscriptomeHumansMaleFemalePrognosisChildChild, Preschool

Stichwörter der Autor:innen

DNA methylationMedulloblastomaPrecision medicinePrognostic biomarker

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Children's Cancer Institute, Porto Alegre, 90620-110, RS, Brazil.
  • Bioinformatics Multidisciplinary Environment-BioME, Digital Metropole Institute, Federal University of Rio Grande do Norte, Natal, 59076-550, RN, Brazil.
  • National Science and Technology Institute for Children's Cancer Biology and Pediatric Oncology - INCT BioOncoPed, Porto Alegre, 90035-003, RS, Brazil.
  • Federal University of Health Sciences of Porto Alegre, Porto Alegre, 90050-170, RS, Brazil.
  • Institute of Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, 90035-003, RS, Brazil.
  • Department of Biochemistry, Federal University of Rio Grande do Norte, Natal, 59064-741, RN, Brazil.

Förderung

  • National Council for Scientific and Technological Development (CNPq, MCTI, Brazil)
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Childrens' Cancer Institute
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Zitieren

APA

Michaelsen, G. L., da Silva, L. D. R. E., de Lima, D. S., Jaeger, M. D. C., Brunetto, A. T., Dalmolin, R. J. S., & Sinigaglia, M. (2024). A Prognostic Methylation-Driven Two-Gene Signature in Medulloblastoma. Journal of Molecular Neuroscience. https://doi.org/10.1007/s12031-024-02203-9

Vancouver

Michaelsen GL, da Silva LDRE, de Lima DS, Jaeger MDC, Brunetto AT, Dalmolin RJS, et al. A Prognostic Methylation-Driven Two-Gene Signature in Medulloblastoma. Journal of Molecular Neuroscience. 2024. doi:10.1007/s12031-024-02203-9

BibTeX
@article{Michaelsen2024,
  author = {Michaelsen, Gustavo Lovatto and da Silva, Lívia Dos Reis Edinger and de Lima, Douglas Silva and Jaeger, Mariane da Cunha and Brunetto, André Tesainer and Dalmolin, Rodrigo Juliani Siqueira and Sinigaglia, Marialva},
  title = {A Prognostic Methylation-Driven Two-Gene Signature in Medulloblastoma},
  journal = {Journal of Molecular Neuroscience},
  year = {2024},
  doi = {10.1007/s12031-024-02203-9}
}
Kostenlos starten →